In recurrent breast tumors, the EMT-driven upregulation of discoidin domain receptor tyrosine kinase 2 (DDR2) maintains growth advantages while also activating YAP/TAZ-mediated ferroptosis susceptibility [114]. The gene discussed is DDR2; the disease is breast neoplasm.